Research summary, original research, 2015

Radiation Exposure in Coronary Angiography: A Comparison of Cineangiography and Fluorography

Hwang J, Lee SY, Chon MK, Lee SH, Hwang KW, Kim JS, et al.. Korean circulation journal. 2015

Read the original paper

In plain language

In 55 selected patients undergoing diagnostic coronary angiography at one Korean centre, using stored fluoroscopy instead of cine roughly halved patient air kerma and dose-area product (DAP) with similar time and contrast use. Staff dose was not measured.

At a glance

Type of study
Original research, Prospective cohort study
Who was studied
Patients, Interventional cardiologists
Size
n = 55 patients
Where
South Korea
Summary based on
the full text

What it found

  • Total air kerma and DAP were roughly halved with fluorography (stored fluoroscopy) compared with conventional cineangiography during diagnostic coronary angiography.

    Key figures: Air kerma (AK) 159.3±64.9 vs 326.9±107.5 mGy; DAP 1337.9±629.6 vs 2341.1±849.9 µGy·m2; p<0.001

  • Procedure time and contrast use did not differ between groups.

    Key figures: 12.8±4.7 vs 12.5±2.9 min, p=0.779; contrast 136.1±28.3 vs 126.3±25, p=0.214

  • Image quality was slightly lower with fluorography but not significantly different and judged acceptable.

    Key figures: adjusted 8.43±0.152 vs 8.32±0.146; p=0.078

  • Only a small share of fluorography cases needed additional cine acquisition.

    Key figures: 2 (10%) patients

Limits to keep in mind

Non-randomized allocation by operator discretion at a single centre with 55 selected, clinically stable patients (BMI ≤30, low heart rate); only patient dose indices were measured, not staff dose.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.